Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-4508 in advanced or metastatic non-small cell lung cancer (NSCLC)
CTR20252096Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-4508 in non-small cell lung cancer (NSCLC), sponsored by Hengrui Therapeutics. Started Oct 2025; status: active.
02
Drugs
HRS-4508
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20252096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252096.